Polysaccharide-Shell Capsules for Stable, Bioavailable Silicic Acid
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of stabilized silicic acid face challenges in achieving high bioavailability, stability, and patient compliance due to hygroscopicity, acidic pH, and unpleasant taste, leading to ineffective dosing and absorption issues.
Innovation Solution
A capsule formulation using a polysaccharide or polysaccharide derivative shell filled with an acidic liquid stabilized silicic acid, stabilized with a quaternary ammonium compound, and optionally containing rheological additives, which maintains stability and bioavailability while allowing for controlled release in the gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If orthosilicic acid is stabilized using quaternary ammonium compounds, then stability against polycondensation is improved, but odor and bitter taste worsen
Solution Approach 1:
The patent extracts the stabilizing function from quaternary ammonium compounds and transfers it to amino acids. The amino acid stabilizer is separated from the orthosilicic acid in the formulation, with the stabilizer being added separately to prevent direct contact that would cause taste issues, while still providing the necessary stabilization against polycondensation.
Solution Approach 2:
The patent introduces amino acids as an intermediary stabilizer between orthosilicic acid and the final formulation. This intermediary substance provides the stabilizing effect without the harmful sensory properties of quaternary ammonium compounds, mediating between the need for stability and the need for acceptable taste and odor.
2Reliability
If stabilized silicic acid is formulated in liquid form, then bioavailability is improved, but hygroscopicity and stability worsen
Solution Approach 1:
The patent changes the pH parameter of the liquid formulation to maintain orthosilicic acid in a stable monomeric form. By controlling the pH and using amino acid stabilizers, the formulation maintains liquid form for bioavailability while preventing polycondensation through chemical parameter control rather than relying on solid carrier materials.
Solution Approach 2:
The patent creates a composite liquid formulation combining orthosilicic acid with amino acid stabilizers and other compatible substances. This composite material provides both the liquid form needed for bioavailability and the chemical stability to prevent polycondensation, integrating multiple functions into a single stable liquid system.
3Stability of the object's composition
If solid formulation with carrier material is used, then stability is improved, but effective silicon concentration and capsule size worsen
Solution Approach 1:
The patent changes the formulation from a solid carrier-based system to a liquid system with controlled pH and amino acid stabilizers. This parameter change allows high concentrations of effective silicon to be achieved in liquid form without requiring large amounts of carrier material, thereby reducing capsule size while maintaining stability.
Solution Approach 2:
The patent extracts the silicic acid from solid carrier materials and formulates it as a concentrated liquid. This extraction eliminates the need for large volumes of inert carrier substances like microcrystalline cellulose, allowing the effective silicon concentration to be maximized within a small capsule volume.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The capsule formulation ensures high stability and bioavailability of silicic acid, enhancing patient compliance and effectiveness in preventing or treating bone-loss, cartilage degeneration, hair loss, nail quality, and skin aging diseases.
Implementation Method 1
OSA may be stabilized by means of a stabilizer, suitably chosen from the group of quaternary ammonium compounds and amino acids
Implementation Method 2
the liquid form of concentrated stabilized-OSA that forms the basis for both liquid and solid formulations is acidic, with a pH around 1, so as to prevent polycondensation
Implementation Method 3
A capsule formulation using a polysaccharide or polysaccharide derivative shell filled with an acidic liquid stabilized silicic acid
Implementation Method 4
which may be converted (particularly by hydrolysis) to orthosilicic acid in the gastro-intestinal tract
Data Source
AI summary
The capsule comprises a capsule shell and filled With an acidic liquid formulation comprising stabilized silicic acid, wherein the capsule shell comprises a polysaccharide and/or a polysaccharide derivative. The stabilization may be achieved with a quaternary ammonium compound. The capsule can be part of a capsule-in-capsule product, wherein the outer capsule contains furthermore a composition such as an oil. The capsule may be applied as a dietary supplement or as a medicament.